Suppr超能文献

70 基因表达谱检测对雌激素受体阳性早期乳腺癌患者辅助化疗决策的影响:一项前瞻性队列研究的结果。

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.

机构信息

Anne Kuijer, Marieke Straver, Bianca den Dekker, Annelotte C.M. van Bommel, and Thijs van Dalen, Diakonessenhuis; Anne Kuijer, Sjoerd G. Elias, Sabine C. Linn, and Thijs van Dalen, University Medical Centre Utrecht; Sabine Siesling, Netherlands Comprehensive Cancer Organization, Utrecht; Carolien H. Smorenburg and Jelle Wesseling, Antoni van Leeuwenhoek Hospital; Carolien H. Smorenburg, Jelle Wesseling, Sabine C. Linn, and Emiel J.Th. Rutgers, Netherlands Cancer Institute, Amsterdam; and Sabine Siesling, University of Twente, Enschede, the Netherlands.

出版信息

J Clin Oncol. 2017 Aug 20;35(24):2814-2819. doi: 10.1200/JCO.2016.70.3959. Epub 2017 Mar 13.

Abstract

Purpose Gene-expression profiles increasingly are used in addition to conventional prognostic factors to guide adjuvant chemotherapy (CT) decisions. The Dutch guideline suggests use of validated gene-expression profiles in patients with estrogen receptor (ER) -positive, early-stage breast cancer without overt lymph node metastases. We aimed to assess the impact of a 70-gene signature (70-GS) test on CT decisions in patients with ER-positive, early-stage breast cancer. Patients and Methods In a prospective, observational, multicenter study in patients younger than 70 years old who had undergone surgery for ER-positive, early-stage breast cancer, physicians were asked whether they intended to administer adjuvant CT before deployment of the 70-GS test and after the test result was available. Results Between October 1, 2013, and December 31, 2015, 660 patients, treated in 33 hospitals, were enrolled. Fifty-one percent of patients had pT1cN0, BRII, HER2-Neu-negative breast cancer. On the basis of conventional clinicopathological characteristics, physicians recommended CT in 270 (41%) of the 660 patients and recommended withholding CT in 107 (16%) of the 660 patients. For the remaining 43% of patients, the physicians were unsure and unable to give advice before 70-GS testing. In patients for whom CT was initially recommended or not recommended, 56% and 59%, respectively, were assigned to a low-risk profile by the 70-GS (κ, 0.02; 95% CI, -0.08 to 0.11). After disclosure of the 70-GS test result, the preliminary advice was changed in 51% of patients who received a recommendation before testing; the definitive CT recommendation of the physician was in line with the 70-GS result in 96% of patients. Conclusion In this prospective, multicenter study in a selection of patients with ER-positive, early-stage breast cancer, 70-GS use changed the physician-intended recommendation to administer CT in half of the patients.

摘要

目的 基因表达谱越来越多地被用于辅助化疗 (CT) 决策,以补充传统的预后因素。荷兰指南建议在雌激素受体 (ER) 阳性、无明显淋巴结转移的早期乳腺癌患者中使用经验证的基因表达谱。我们旨在评估 70 基因特征 (70-GS) 检测对 ER 阳性、早期乳腺癌患者 CT 决策的影响。

患者和方法 在一项针对年龄小于 70 岁的接受 ER 阳性、早期乳腺癌手术的患者的前瞻性、观察性、多中心研究中,在部署 70-GS 检测之前和获得检测结果后,医生被问及他们是否打算进行辅助 CT。

结果 2013 年 10 月 1 日至 2015 年 12 月 31 日,共纳入 660 例患者,在 33 家医院接受治疗。51%的患者为 pT1cN0、BRII、HER2-Neu 阴性乳腺癌。基于传统的临床病理特征,医生建议对 660 例患者中的 270 例(41%)进行 CT,建议对 660 例患者中的 107 例(16%)不进行 CT。对于其余 43%的患者,医生在进行 70-GS 检测之前无法确定并提供建议。在最初建议进行 CT 或不建议进行 CT 的患者中,分别有 56%和 59%的患者被 70-GS 检测分配到低风险组(κ,0.02;95%CI,-0.08 至 0.11)。在披露 70-GS 检测结果后,在接受检测前接受建议的 51%的患者中,初步建议发生改变;医生的明确 CT 建议与 96%的患者的 70-GS 结果一致。

结论 在这项针对 ER 阳性、早期乳腺癌患者的选择患者的前瞻性、多中心研究中,70-GS 的使用改变了一半患者的医生意向性 CT 治疗建议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验